Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indoco RemediesBOM:532612 -0.25%65 EBITDA Margin % is 30.14% as of Jun. 2026, which is 117% above its 10-year median of 13.87. GuruFocus rates BOM:532612 with a GF Score™ of 65/100 and a GF Value™ of ₹342.64 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Indoco Remedies ranks better than 55.15% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Indoco Remedies's EBITDA for the
three
months ended in Jun. 2026 was ₹1,405 Mil. Indoco Remedies's Revenue for the
three
months ended in Jun. 2026 was ₹4,662 Mil. Therefore, Indoco Remedies's EBITDA margin for the quarter that ended in Jun. 2026 was 30.14%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Indoco Remedies EBITDA Margin % Related Terms
Indoco Remedies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Indoco Remedies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Indoco Remedies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indoco Remedies EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indoco Remedies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Indoco Remedies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indoco Remedies (BOM:532612) has a EBITDA Margin % of 30.14% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indoco Remedies and its competitors. This is 117% above median its historical median of 13.87. Over the past decade, Indoco Remedies' EBITDA Margin % has ranged from 6.44 to 21.96. According to the industry distribution chart, Indoco Remedies ranks #431 out of 961 companies in the Drug Manufacturers industry, placing it in the top 44.8%.
Is Indoco Remedies' EBITDA Margin % too high?
Indoco Remedies' current EBITDA Margin % of 30.14% is 117% above median its 10-year median of 13.87. Over the past 10 years, this metric has ranged from a low of 6.44 to a high of 21.96. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Indoco Remedies' value of 30.14% is 143.3% above this industry median. Based on the distribution chart, Indoco Remedies ranks #431 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Indoco Remedies has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indoco Remedies' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Indoco Remedies ranks #431 out of 961 companies for EBITDA Margin %. This puts Indoco Remedies in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Indoco Remedies' value of 30.14% is 143.3% above this benchmark. Historically, Indoco Remedies' own EBITDA Margin % has ranged from 6.44 to 21.96 over the past decade. While the company's 10-year median is 13.87 vs. the industry median of 12.39, Indoco Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indoco Remedies's current EBITDA Margin % of 30.14% is 143.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indoco Remedies and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indoco Remedies's current EBITDA Margin % is 30.14%, which is 117% above median its own 10-year median of 13.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indoco Remedies stock overvalued right now?
Based on GuruFocus' analysis, Indoco Remedies (BOM:532612) is currently considered Possible Value Trap. The stock's GF Value™ is ₹342.64, compared to a current price of ₹222.85 — trading 35% below its estimated fair value. The current EBITDA Margin % is 30.14%, which is 117% above median its 10-year median of 13.87 and 143.3% above the Drug Manufacturers industry median of 12.39. Indoco Remedies' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Indoco Remedies (BOM:532612), the current EBITDA Margin % is 30.14% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indoco Remedies (BOM:532612) Overvalued in 2026?
Based on GuruFocus' analysis, Indoco Remedies stock appears to be undervalued.
The current stock price of ₹222.85 is trading 35% below its estimated GF Value™ of ₹342.64.
GuruFocus considers Indoco Remedies to be Possible Value Trap.
Key valuation signals for BOM:532612:
EBITDA Margin %: 30.14% (117% above median its 10-year median of 13.87)
GF Value™: ₹342.64 vs. price of ₹222.85 (35% below fair value)
Industry Position: 143.3% above the Drug Manufacturers median (#431 of 961)
No single metric tells the full story. See the BOM:532612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indoco Remedies Ltd is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The company manufactures products for different therapeutic sectors including Gastroenterology, Dentistry & Stomatology, Respiratory, Diabetology, Women's Health, Nutritional products, Cardiology, Metabolic Disorders, and Primary Care medicines. The only operating segment of the company is Pharmaceutical Products. Geographically, it generates the majority of the revenue from India.
65GF Score
Get the complete analysis for BOM:532612
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532612 has been successfully added to your 
